Cencora, Inc. (NYSE:COR) Shares Purchased by Ferguson Wellman Capital Management Inc.

Ferguson Wellman Capital Management Inc. grew its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 1.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 129,086 shares of the company's stock after acquiring an additional 2,322 shares during the quarter. Ferguson Wellman Capital Management Inc. owned 0.07% of Cencora worth $35,898,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD boosted its holdings in Cencora by 0.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 8,859,452 shares of the company's stock worth $1,990,542,000 after acquiring an additional 78,066 shares in the last quarter. Bank of America Corp DE raised its stake in shares of Cencora by 62.3% in the fourth quarter. Bank of America Corp DE now owns 5,193,807 shares of the company's stock worth $1,166,944,000 after purchasing an additional 1,994,256 shares during the last quarter. Boston Partners raised its stake in shares of Cencora by 2.6% in the fourth quarter. Boston Partners now owns 5,007,100 shares of the company's stock worth $1,128,058,000 after purchasing an additional 125,611 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Cencora by 3.1% in the fourth quarter. Geode Capital Management LLC now owns 4,326,064 shares of the company's stock worth $969,471,000 after purchasing an additional 130,213 shares during the last quarter. Finally, Invesco Ltd. raised its stake in shares of Cencora by 20.4% in the fourth quarter. Invesco Ltd. now owns 3,243,531 shares of the company's stock worth $728,757,000 after purchasing an additional 550,246 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on COR. Morgan Stanley set a $288.00 price objective on Cencora in a research note on Tuesday, April 15th. Robert W. Baird lifted their price target on Cencora from $314.00 to $350.00 and gave the company an "outperform" rating in a research report on Thursday, May 8th. Wells Fargo & Company upgraded Cencora from an "equal weight" rating to an "overweight" rating and lifted their price target for the company from $274.00 to $337.00 in a research report on Tuesday, June 3rd. Wall Street Zen upgraded Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. Finally, Citigroup boosted their price objective on Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $306.91.

Cencora Trading Up 0.0%

Shares of COR stock traded up $0.08 on Friday, hitting $295.12. The stock had a trading volume of 966,888 shares, compared to its average volume of 1,528,880. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. The firm has a market capitalization of $57.20 billion, a P/E ratio of 41.98, a P/E/G ratio of 1.31 and a beta of 0.58. Cencora, Inc. has a 1 year low of $218.65 and a 1 year high of $309.35. The company's 50 day moving average price is $287.24 and its 200-day moving average price is $261.82.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, topping the consensus estimate of $4.07 by $0.35. Cencora had a return on equity of 328.62% and a net margin of 0.46%. The company had revenue of $75.50 billion for the quarter, compared to the consensus estimate of $75.41 billion. During the same quarter in the prior year, the business earned $3.80 EPS. Cencora's revenue was up 10.3% on a year-over-year basis. Analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, June 2nd. Shareholders of record on Friday, May 16th were issued a dividend of $0.55 per share. The ex-dividend date was Friday, May 16th. This represents a $2.20 annualized dividend and a yield of 0.75%. Cencora's dividend payout ratio (DPR) is 25.52%.

Insiders Place Their Bets

In related news, CEO Robert P. Mauch sold 4,969 shares of the company's stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $289.33, for a total value of $1,437,680.77. Following the completion of the sale, the chief executive officer now directly owns 47,582 shares of the company's stock, valued at $13,766,900.06. This represents a 9.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Elizabeth S. Campbell sold 4,127 shares of the company's stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $268.28, for a total value of $1,107,191.56. Following the completion of the sale, the executive vice president now directly owns 14,665 shares of the company's stock, valued at approximately $3,934,326.20. This trade represents a 21.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 38,253 shares of company stock worth $10,582,297 in the last quarter. 10.80% of the stock is owned by company insiders.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.